Qualigen Therapeutics IncNASDAQ:QLGNNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.2905
- TODAY'S CHANGE (%)-0.0065 (-2.1886%)
- Bid / Lots0.2900/ 20
- Ask / Lots0.3070/ 35
- Open / Previous Close0.3000 / 0.2970
- Day Range
- 52 Week Range
- Volume9,216
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | QLGN |
|---|---|---|
| 09:36 ET | 249 | 0.3 |
| 09:41 ET | 734 | 0.304 |
| 10:03 ET | 100 | 0.319 |
| 10:46 ET | 1000 | 0.3 |
| 12:59 ET | 1580 | 0.315 |
| 01:15 ET | 1986 | 0.3 |
| 02:08 ET | 1000 | 0.302699 |
| 02:11 ET | 1015 | 0.303 |
| 02:36 ET | 100 | 0.3027 |
| 02:47 ET | 125 | 0.302701 |
| 03:23 ET | 200 | 0.311 |
| 03:59 ET | 100 | 0.2905 |
Apr 16, 2024
Marizyme Enters Into Co-Development Agreement With Qualigen Therapeutics for the Commercialization of FDA-Cleared DuraGraft(TM), from 7:00AM ET on Tuesday Apr 16, 2024 by Dow Jones
7:00AM ET on Tuesday Apr 16, 2024 by Dow Jones
Apr 10, 2024
Qualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting, from 8:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
8:00AM ET on Wednesday Apr 10, 2024 by Dow JonesQualigen Therapeutics' Novel Direct Pan-RAS Inhibitors Presented at American Association of Cancer Research (AACR) 2024 Annual Meeting, from 8:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
8:00AM ET on Wednesday Apr 10, 2024 by Dow Jones
Apr 9, 2024
Qualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting, from 8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 09, 2024 by Dow JonesQualigen Therapeutics Announces Poster Featuring Positive Early Clinical Experience with QN-302, a Novel First-in-Class G-Quadruplex Experimental Anti-Cancer Drug, at the American Association of Cancer Research (AACR) 2024 Annual Meeting, from 8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
8:00AM ET on Tuesday Apr 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Qualigen Therapeutics Inc | 1.9M | -0.1x | --- |
Scinai Immunotherapeutics Ltd | 2.0M | -0.1x | --- |
CTT Pharmaceutical Holdings Inc | 2.1M | -0.5x | --- |
VG Life Sciences Inc | 2.1M | 0.0x | --- |
Virax Biolabs Group Ltd | 1.7M | -0.5x | --- |
Panbela Therapeutics Inc | 2.1M | 0.0x | --- |
Company Information
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
Contact Information
- Headquarters
- 1880 Century Park E Ste 1000LOS ANGELES, CA, United States 90067-1623
- Phone
- 310-203-1000
- Fax
- 310-919-1600
Executives
- Chairman of the Board, Chief Executive Officer
- Michael Poirier
- Chief Financial Officer, Vice President - Finance
- Christopher Lotz
- Chief Scientific Officer, Vice President - Research and Development
- Wajdi Abdul-Ahad
- Director
- Ira Ritter
- Independent Director
- Richard David
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.9M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 6.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -0.74 |
EPS | $-2.46 |
Book Value | $-0.39 |
P/E Ratio | -0.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
